GlassScriptPhysician profile
Babak Pazooki
NPI 1396762316
$581,665.41
in general payments reported to CMS, 2019-2025
31 companies · $117K in 2025
The $117K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $39K · 2021: $64K · 2022: $57K · 2023: $78K · 2024: $117K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $275K · Travel and Lodging: $17K · Food and Beverage: $8,403 · Consulting Fee: $8,363 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,813 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $275,012.34 |
| Travel and Lodging | $17,447.04 |
| Food and Beverage | $8,403.27 |
| Consulting Fee | $8,362.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,812.50 |
| Education | $109.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $182,917.65 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $137,778.93 | 2019-2025 | |
| Novo Nordisk INC | $117,980.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $63,917.86 | 2019-2024 | Farxiga, Breztri |
| Abbott Laboratories | $30,746.61 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $20,556.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $18,840.08 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $5,085.53 | 2021-2025 | |
| Madrigal Pharmaceuticals | $1,842.61 | 2025 | Rezdiffra |
| Insulet Corporation | $236.85 | 2019-2025 | Omnipod |
| Dexcom, INC. | $173.82 | 2020-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $161.72 | 2022-2023 | Korlym |
| Amgen INC. | $156.62 | 2020-2025 | Tepezza |
| Becton, Dickinson and Company | $154.72 | 2019 | |
| Shire North American Group INC | $146.45 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.69 | 2019-2023 | |
| Mannkind Corporation | $125.00 | 2021 | |
| Tolmar, INC. | $107.74 | 2024 | |
| Amarin Pharma, INC. | $106.52 | 2021 | |
| Chiesi USA, INC. | $93.99 | 2024 | Mycapssa |
| Dynavax Technologies Corporation | $81.91 | 2024 | Heplisav-B |
| Abbvie INC. | $67.91 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $52.94 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Horizon Therapeutics Plc | $31.74 | 2023 | Tepezza |
| Sequel Med Tech, LLC | $21.50 | 2025 | Twiist |
| Beta Bionics, INC. | $20.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Exact Sciences Corporation | $19.18 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $16.99 | 2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.80 | 2024 | Xifaxan |
| Medtronic, INC. | $15.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Pazooki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.